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Abstract
Diabetic nephropathy (DN) is a leading cause of end stage renal disease. Diabetic vascular
complications like DN can progress despite subsequent glycemic control, suggesting a metabolic
memory of previous exposure to hyperglycemia. Diabetes profoundly impacts transcription
programs in target cells through activation of multiple signaling pathways and key transcription
factors leading to aberrant expression of pathological genes. Emerging evidence suggests that
these factors associated with the pathophysiology of diabetic complications and metabolic
memory might also be influenced by epigenetic mechanisms in chromatin such as DNA
methylation, histone lysine acetylation and methylation. Key histone modifications and the related
histone methyltransferases and acetyltransferases have been implicated in the regulation of
inflammatory and pro-fibrotic genes in renal and vascular cells under diabetic conditions
Advances in epigenome profiling approaches have provided novel insights into the chromatin
states and functional outcomes in target cells affected by diabetes. Because epigenetic changes are
potentially reversible, they can provide a window of opportunity for the development of much
needed new therapies for DN in the future. In this review we discuss recent developments in the
field of epigenetics and their relevance to diabetic vascular complications and DN pathogenesis.
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Introduction
A global surge in the incidence of diabetes and metabolic disorders has greatly increased the
risk for multiple associated complications. Diabetes leads to severe complications in several
major organs including eyes, heart, nerves and kidney that lead to reduced quality of life and
increased mortality rates. More than 40% of patients with diabetes develop diabetic
nephropathy (DN), a microvascular complication and chronic kidney disease that leads to
progressive renal dysfunction and is a leading cause of end stage renal disease (ESRD).
Furthermore, DN also increases the risk for cardiovascular diseases (CVD). Diabetes
profoundly impacts transcription programs of cells in target tissues via the activation of
multiple signaling pathways and key transcription factors (TFs) leading to aberrant
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expression of pro-inflammatory and pro-fibrotic genes involved in DN pathogenesis1–3.
Emerging evidence suggests that these factors associated with the pathophysiology of
diabetes and its complications might also be influenced by epigenetically regulated
mechanisms in chromatin such as DNA methylation (DNAme), and histone lysine
acetylation (HKac) and methylation (HKme)4, 5. Apart from genetic predisposition, it is now
clear that additional factors, like changes in the environment and lifestyles that affect
epigenetic states, can influence the etiology and progression of common human diseases like
diabetes and DN. Thus, the study of epigenetic mechanisms can offer valuable and novel
new insights into the pathophysiology of diabetes and susceptibility to the associated
complications. Rapid developments in high throughput genomic approaches such as next
generation DNA sequencing (NGS) and efforts of several world-wide consortia have yielded
enormous and significant information about chromatin states and the epigenome under
normal and disease states that also have the potential to reveal functions of genetic variants
at various genome locations6, 7. These exciting advances in the field of epigenetics can be
exploited to enhance our understanding of the molecular mechanisms involved in the DN
pathogenesis. Furthermore, because, unlike genetic variants, epigenetic changes are
potentially reversible, they could be used to not only identify novel biomarkers for early
disease detection, but also for the development of new therapeutic targets for DN, a
debilitating complication of diabetes. In this review we discuss the recent developments in
the field of epigenetics and their relevance to the pathogenesis of DN.
Diabetic Nephropathy and Metabolic Memory
DN is clinically characterized by proteinuria, albuminuria, rising creatinine levels, and
aberrant glomerular filtration rates. The key histological and pathological features of DN
include renal glomerular hypertrophy, mesangial expansion and tubulointerstitial fibrosis
due to accumulation of extracellular matrix (ECM) proteins such as collagens and
fibronectin, thickening of the basement membrane, podocyte loss and foot process
effacement. Endothelial dysfunction and inflammation due to macrophage infiltration also
play important roles in DN pathogenesis1, 8.
Hyperglycemia as well as complex interactions between metabolic and hemodynamic
factors are linked to the development of diabetic complications including DN1, 9. High
glucose (HG) adversely impacts all cell types in the kidney including mesangial cells (MC),
tubular cells, podocytes, endothelial cells (EC) and infiltrating monocytes/macrophages. It
increases the formation of advanced glycation end products (AGEs) and levels of growth
factors like transforming growth factor-beta1 (TGF-β1) and Angiotensin II (Ang II) in renal
cells. TGF-β levels are increased in most renal cells in diabetes and is a major player in DN
pathogenesis mainly due to its profibrotic actions1, 3. Cross-talk between these diabetogenic
factors can amplify and perpetuate the expression of pathologic genes associated with the
progression of DN (Fig. 1). Multiple signal transduction mechanisms and kinases including
oxidant stress, protein kinase C, Akt kinase, receptor and non-receptor protein tyrosine
kinases have been implicated in the activation of key effector TFs such as Smads and NF-κB
downstream of HG and growth factors leading to increased production of pro-inflammatory
cytokines, cell cycle genes, profibrotic and ECM genes involved in DN1, 3. Recently,
microRNA (miRNA) mediated mechanisms have also been implicated10. Despite such
advances in the understanding of the biochemical and molecular mechanisms leading to DN,
currently available therapies are still not fully effective in preventing progression to ESRD,
suggesting that additional mediators and mechanisms need to be explored.
One of the potential reasons for the long term progression of diabetic complications could be
a ‘metabolic memory’ of prior exposure of target cells to HG leading to persistence of its
deleterious effects long after glucose normalization11 (Fig. 1). This memory phenomenon
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has been identified in experimental models as well as clinical trials such as the Diabetes
Control and Complications Trial (DCCT) and the follow-up observational Epidemiology of
Diabetes Intervention and Complications (EDIC) study. The results of the DCCT
demonstrated that patients with type 1 diabetes (T1D) placed on strict glycemic control with
intensive insulin therapy had much lower incidence or severity of various complications,
including nephropathy and neuropathy relative to those who were on standard/conventional
therapy 12. Following the conclusion of the DCCT study, both conventional and intensive
treatment DCCT groups were placed on intensive therapy and followed long-term in the
EDIC study phase. Despite attainment of similar levels of HbA1c in both groups during
EDIC, patients who were previously in the intensive therapy group during DCCT had
significantly lower risks of developing microvascular complications (neuropathy and
nephropathy) as well as macrovascular complications13, 14 relative to the original DCCT
conventional treatment group, a phenomenon termed metabolic memory. Clinical trials of
glycemic control in type 2 diabetes patients (UKPDS) have found a similar phenomenon
referred to as a ‘legacy effect’15.
With respect to experimental models of metabolic memory, in early studies, Lorenzi and co-
workers first reported a glycemic memory phenomenon in an animal and cell culture
model 16. More recently, reports show that vascular smooth muscle cells (VSMC) from type
2 diabetic db/db mice exhibited enhanced pro-inflammatory responses relative to those from
non-diabetic control db/+ mice even after culturing outside the animals for few weeks17. In
cultured EC, HG induced changes in the expression of inflammatory and oxidant stress
genes persisted even after returning to normal glucose18, 19. Furthermore, in experiments
with type 1 diabetic dogs or rats, approaches to re-institute good glycemic control following
several weeks of poor glycemic control did not prevent progression to retinopathy and
nephropathy, demonstrating a memory of early hyperglycemia20–22. Since metabolic
memory remains a major obstacle in the effective prevention and treatment of diabetic
complications, there is much interest in determining the mechanisms underlying metabolic
memory and in recent years, epigenetic factors have been implicated.
Epigenetics and the Epigenome: Why study this in Diabetic Nephropathy?
Epigenetics was originally defined by Waddington as ‘the causal interactions between genes
and their products which bring the phenotype into being’ and mainly referred to changes
during embryonic development23. A more commonly used definition of epigenetics is “the
study of heritable changes in gene expression that occur without alterations in the underlying
DNA sequences”. More recently this has been further refined as ‘the structural adaptation of
chromosomal regions so as to register, signal, or perpetuate altered activity states’, to also
account for alterations in the chromatin state and structure in response to various cues24, 25.
Epigenetic mechanisms establish and maintain the chromatin structure to confer
transcription memory important for the faithful transmission of gene expression patterns
across multiple cell divisions even in the absence of signals that initiated them.. Epigenetic
control of gene regulation plays an important role in embryogenesis, development, cell
identity, stable inheritance of gene expression patterns in differentiated cells, genomic
imprinting, X-chromosome inactivation, immune cell function, stem cell plasticity,
differential disease susceptibility between monozygotic twins, and cellular responses to
environmental signals26, 27.
In mammalian cells, chromosomal DNA is tightly packaged into ‘chromatin’, a higher order
structure made up of arrays of subunits called nucleosomes. Each nucleosome consists of an
octamer protein complex containing two copies each of core histone proteins H2A, H2B, H3
and H4, wrapped around by 147 bp chromosomal DNA. Posttranslational modifications
(PTMs) of nucleosomal histones and DNA methylation (DNAme) represent epigenetic
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modifications (Fig. 2) 26, 27. These modifications, along with non-coding RNAs including
short non-coding microRNAs (miRNAs) and long non coding RNAs (lncRNAs), regulate
chromatin function and are collectively labeled as the ‘epigenome’, which stores the
epigenetic information needed for the cell-type specific gene expression patterns. Recent
advances in high throughput genomewide profiling and sequencing approaches have led to a
broader understanding of various aspects of the epigenome and its correlations to
phenotype6, 28. Alterations in epigenome states have a profound effect on gene regulation
and biological outcomes and are implicated in the pathogenesis of various disorders
including cancer29, 30. Furthermore, persistence of aberrant epigenetic marks, even after
withdrawal of the original stimuli, can mediate disease progression and resistance to
conventional therapies. Lifestyle choices like overeating can influence the epigenetic
mechanisms leading to aberrant expression of genes involved in metabolic disorders and
cardiovascular diseases4, 11. Notably, intrauterine environment and maternal nutrition can
promote epigenetic changes to control the onset of metabolic abnormalities in adult life31.
The heritable nature of epigenetic marks could also predispose future generations for
metabolic abnormalities and reduced lifespan32. It is worth examining whether they also
affect the development of complications like DN later in life. The importance of epigenetic
mechanisms in diabetes and its complications has only recently been appreciated
Understanding how diet, physical activity and environmental factors influence the
epigenome could provide novel new insights into the pathogenesis of diabetes complications
like DN and metabolic memory, and hence to newer therapeutic modalities and diagnostic
biomarkers for early intervention. Since genome wide association studies (GWAS) have
uncovered only limited candidate susceptible genes for DN, evaluation of epigenotypes by
epigenome wide association studies (EWAS) may provide critical new information.
DNA methylation and its role in diabetes and DN
DNAme is the most well established epigenetic mark. It occurs at 5′-Cytosines of ‘CpG’
dinucleotides, which tend to form clusters known as CpG islands at key genome regions.
Both DNA methyl transferase 3A (DNMT3A) and DNMT3B mediate denovo DNAme,
whereas DNMT1 acts as a maintenance methyltransferase using S-Adenosyl-methionine as
a co-factor 27, 33. Emerging evidence shows the presence of active DNA demethylation
suggesting DNAme is more dynamic than thought earlier. While key oxidases have been
implicated, the mechanisms mediating DNA de-methylation in mammalian systems are not
yet fully understood27, 33. Generally DNAme at promoter regions leads to gene repression,
whereas at gene bodies it might regulate transcription elongation and alternative splicing.
Studies also implicate DNAme in the activity of other transcription regulatory elements such
as enhancers and insulators27. DNAme is recognized by methyl binding proteins including
methyl-CpG binding protein 2 (MeCP2), which can recruit transcriptional co-repressors via
protein-protein interactions to inhibit gene expression. Furthermore, DNAme itself can
inhibit binding of TFs at promoters to block gene expression27.
In the context of diabetes, the role of DNAme has been studied in the transgerational
inheritance of metabolic diseases which have led to the hypothesis that environment and diet
may influence epigenetic modifications at imprinted genes, transposable elements and repeat
elements in genomic DNA to regulate disease pathogenesis31. A role for DNAme has also
been suggested in Intrauterine growth restriction (IUGR) induced effects on the fetal
epigenome that can reprogram the timing and intensity of gene expression leading to
metabolic abnormalities later in adult life34. Aberrant DNAme has been reported in the
reduced expression of genes involved in insulin expression, signaling and energy
metabolism in islets and skeletal muscle in diabetes and the metabolic syndrome35–39. HG
and free fatty acids could regulate DNAme suggesting nutrient excess can lead to
dysregulation of DNAme and alter expression of genes linked with susceptibility to obesity
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and diabetes36, 38. Variations in DNAme have also been recently implicated in the
expression of diabetes susceptibility genes40, 41. Such studies may help confer functionality
to disease associated single nucleotide polymorphisms42.
A few studies have investigated a role for DNAme in the pathogenesis of DN and
ESRD5, 43, 44. Assessment of DNAme in whole blood genomic DNA obtained from diabetic
patients with DN relative to those without DN revealed differential methylation in a number
of genes including UNC13B which has been previously linked with DN43. Another study
identified a number of regions with differential DNAme in the saliva samples of patients
with ESRD relative to those with CKD alone44. On the other hand some studies in renal cell
culture models under diabetic conditions or DN animal models did not show significant
changes in DNAme5. Another interesting report showed that DNAme can play a role in a
model of fibrosis and in TGF-β1 actions. The authors found that hypermethylation of
RASAL1 can increase Ras activation in fibroblasts, leading to proliferation and fibrosis45.
Sequencing approaches in EC showed that HG could induce alterations in DNAme at key
genes involved in endothelial cell dysfunction46. Because fibrotic gene expression and EC
dysfunction are involved in DN pathogenesis, abnormalities in DNAme in EC and other
renal cells in vivo might contribute to changes in the expression of genes associated with
DN. Additional studies are needed with key renal cells including podocytes, mesangial and
tubular cells, as well as with renal tissues and biopsies obtained from animal models of DN
and humans at various stages of DN, to identify abnormalities in DNAme patterns that may
be specifically linked with DN.
Histone Modifications
Covalent posttranslational modifications (PTMs) of nucleosomal histone proteins are now
known to play important roles in gene regulation26. Several histone PTMs have been
identified including lysine (K) acetylation (Kac), methylation (Kme) and ubiquitination, Ser/
Thr phosphorylation and Arginine methylation. Histone PTMs occur mostly in the exposed
amino-terminal tails with some exceptions. The involvement of histone Kac and Kme in
gene transcription has been extensively studied and will be discussed here26, 28. In general,
histone Kac (such as H3K9ac, H3K14ac, H4K5ac) at gene promoters correlates with
transcriptional activation whereas its removal is associated with gene repression. Histone
Kme can be associated with either gene activation or repression depending on the amino
acid residue modified and the extent of methylation i. e., mono (Kme), di (Kme2) or tri
(Kme3) methylation. H3K4me1/2/3 and H3K36me2/3 are generally associated with
transcriptionally active genome regions, whereas H3K9me3, H3K27me3 and H4K20me3
with repressed regions26. Genomewide mapping has led to the discoveries that distinct
patterns of specific histone modifications can distinguish key regulatory regions of the
genome including promoters, enhancers, exons, introns, intergenic regions and repetitive
elements6, 28 (Fig. 2). Transcriptionally active gene promoters are enriched with H3K9Ac,
H3K4me2 and H3K4me3 while gene bodies and transcribed regions are enriched with
H3K36me3 and H3K79me3. On the other hand, inactive or silent gene promoters are
enriched with repressive marks H3K9me3 and H3K27me36, 28. In general, enhancers are
difficult to identify, but this has changed with the discoveries that they are enriched with
H3K4me1 and also H3K27ac47 (Fig. 2). Bivalent promoters in developmental genes are
enriched with both active (H3K4me3) and repressive (H3K27me3) marks and are therefore
in a poised state6, 28. Furthermore, enrichment of H3K27me3 at the beginning of gene
bodies is associated with inhibition of transcription elongation48. Histone H3K4me3 and
H3K36me3 chromatin marks are recognized to be associated with active transcription.
Hence, mapping of their enrichment profiles genome-wide is now a well established method
to identify known and novel transcripts including non coding RNAs (ncRNAs) that do not
have a coding potential but can modulate the epigenetic machinery 49.
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Histone Kac is mediated by histone acetyl transferases (HAT) such as p300, CBP and TIP60
which can also act as transcription co-activators. Conversely, histone deacetylases (HDAC)
including HDAC1-11 and Sirtuins remove acetylation marks and in general act as co-
repressors with some exceptions. Sirtuins have generated lot of interest since they are
regulated by energy metabolism50. Kme is mediated by histone lysine methyl transferases
(HMTs) and erased by histone lysine demethylases (HDMs). HMTs and HDMs are highly
specific to the lysine residue being modified and the extent of methylation (Kme1/2/3).
SUV39H1, the first HMT to be identified, mediates H3K9me3 (a repressive mark), whereas
Lysine specific demethylase 1 (LSD1), the first demethylase identified, removes H3K4me1/
me2. H3K27me3 is mediated by Ezh2 and the Polycomb Repressive Complex (PRC), while
H3K4me is mediated by SET7 (H3K4me1) and members of the MLL family
(H3K4me1/2/3). SET2 mediates H3K36me3 and DOT1a regulates H3K79me3. Among
other demethylases, JMJD1A demethylates H3K9me2, but H3K9me3 is removed by
JMJD2A. JMJD3 removes H3K27me3, while JARID1A removes H3K4me3. The SET
domain present in most HMTs catalyzes Kme using S-adenosyl methionine (SAM) as a co-
factor, whereas HDMs demethylate via an amino oxidase domain (in LSD1) or JmjC
domain (JMJD2A) and use FAD and α-ketoglutarate as co-factors respectively51.
Histone modifying enzymes can be recruited to promoters by binding to specific DNA
sequences in the promoters such as PRC response elements, or by binding to pre-existing
modifications or via interaction with RNA Polymerase II and TFs52. Recent studies
demonstrated that ncRNAs can also bind to HMTs and HDMs and target them to specific
genome locations53. Histone modification enzymes can also modify lysine residues on non-
histone proteins including TFs, adding another level of complexity54. Therefore, a new
nomenclature has been proposed for HMTs and HDMs based on their enzymatic activity and
the order of discovery, e.g., SUV39H1 and MLL have been renamed as KMT1A and
KMT2A respectively54. The specificity of HMTs and HDMs can be modified by altering
key amino acids in their catalytic domains suggesting that such mutations in humans can
potentially be involved in disease pathogenesis. Furthermore, because histone modifying
enzymes use metabolites such as acetyl-CoA (HATs), SAM (HMTs) and α-ketoglutarate
(HDMs) as cofactors, they might act as metabolic sensors. As such, mis-regulation of their
function by factors such as diet and environment can lead to metabolic abnormalities55. The
role of DNAme in epigenetic transmission is more widely studied than that of histone PTMs,
although recent studies have suggested that the histone modifiers like PRC proteins and
histone recycling can be involved56, 57. Overall, the cross-talk between histone PTMs,
DNAme and ncRNAs provides another layer of epigenetic regulation and their impact on
transcription processes is being increasingly appreciated53, 58. The continuous interplay
between these epigenetic modifications and the environment regulates multitudes of
responses from a single eukaryotic genome in diverse cell types, which if dysregulated, can
result in diabetes and its cardiovascular and renal complications.
Histone PTMs and Diabetes
Histone PTMs regulate chromatin structure and gene expression by recruiting chromatin
remodeling proteins, transcription co-activators, and co-repressors26. Emerging evidence
shows the involvement of key histone PTMs in the regulation of genes associated with the
pathogenesis of diabetes. Regulation of insulin gene expression as well as its secretion from
islets in response to changing glucose levels is a key process in glucose homeostasis, one
that is dysregulated in diabetes. Studies show that the islet specific TF Pdx-1 can modulate
this process of insulin regulation through epigenetic mechanisms59. In response to elevated
glucose conditions, Pdx1 recruits co-activator HATs p300 and CBP and a HMT SET7/9
(SET7), which increases activation marks H3/H4Kac and H3K4me2 respectively at the
insulin promoter to promote open chromatin formation accessible to transcription machinery
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and enhance insulin transcription59, 60. In contrast, under low glucose conditions, Pdx1
recruits co-repressors HDAC1 and HDAC2, promoting chromatin compaction and inhibition
of insulin expression59. Interestingly, Pdx-1 also controls the islet specific expression of
SET7 by direct interaction with its promoter60. Genomewide mapping of HK4me1,
H3K4me3, H3K79me2 in islets revealed several islet specific promoters and enhancers.
Furthermore, several regulatory elements located near diabetes susceptible loci exhibited
allele specific differences in their activity61. Another study also mapped open chromatin
regions in islets and identified association of allele specific differences in enhancer activity
with genetic variations near diabetes susceptible loci62 further highlighting how genetic
variations in non-coding regions might affect chromatin structure in diabetes. Histone PTMs
along with DNAme were also found to play an important role in epigenetic regulation of
Pdx1 and insulin expression in islets of diabetic offspring from IUGR rats, suggesting that
histone PTMs can be affected by maternal malnutrition34.
Adipogenesis plays an important role in the pathogenesis of metabolic abnormalities and is
tightly controlled by the transcription factors C/EBPβ and PPARγ. Dynamic changes in
histone PTMs and recruitment of the corresponding modifiers can regulate C/EBPβ and
PPARγ induced gene expression involved in adipocyte differentiation63, 64. Interestingly,
epigenetic inactivation of PPARγ has been demonstrated in adipocytes from type 2 diabetes
(T2D) animals65 further supporting a role for epigenetic processes in adipocyte dysfunction
and T2D. Another study reported increased predisposition to obesity and metabolic
syndrome in mice deficient in Jhdm2a, a H3K9me2 demethylase, demonstrating that
deficiency in key histone modifying enzymes might contribute to metabolic abnormalities66.
Overall, these studies highlight how alterations in chromatin structure can contribute to
diabetes development. This is clearly a research area likely to show increased activity in the
upcoming years. It is possible that epigenetic changes that contribute to the pathology of
diabetes can also directly or indirectly affect target organs leading to complications.
Histone PTMs and gene regulation in Diabetic Nephropathy
Accumulating evidence shows that epigenetic regulation of gene expression plays important
roles in kidney development and other renal disorders such as acute kidney injury 5, 67 that
will not be discussed here. Because very few genetic loci have been found to be associated
with CKD and DN, it is increasingly felt that epigenetics could also be involved. Reports
from studies in cell culture and animal models show that epigenetic histone PTMs are
involved in the expression of key genes associated with DN pathogenesis. TGF-β signaling
plays an important role in the expression of fibrotic and ECM genes such as Collagen 1alpha
2 (Col1a2), plasminogen activator inhibitor 1 (PAI-1) and cell cycle inhibitor p21 in renal
cells, which contribute to DN pathogenesis1. TGF-β regulates gene expression mostly
through activation of the TFs Smad 2, Smad3 and Smad4, which can collaborate with HATs
and chromatin remodeling factors1, 68. TGF-β can also mediate the effects of HG1, 3. Recent
studies examined these mechanisms as well as histone Kac and Kme in rat MC (RMC)
treated with TGF-β and HG. TGF-β increased H3K9/14ac near Smad and SP1 binding sites
by recruiting the HATs p300 and CBP to the PAI-1 and p21 promoters. Co-transfection
experiments showed that CBP and p300, but not p/CAF, increased transcriptional activity of
PAI-1 and p21 promoters and enhanced TGF-β induced gene expression. In contrast,
inhibition of these HATs by overexpressing dominant negative mutants lacking HAT
activity blocked TGF-β induced gene expression. Furthermore, over expression of HDAC1
and HDADC5 inhibited TGF-β induced gene expression, whereas, inhibition of HDACs
increased H3K9/14ac and gene expression further supporting a key role for histone Kac and
HATs in TGF-β induced gene expression69. TGF-β also increased association of p300 with
Smads2/3 and SP1, and increased acetylation of Smads in RMC69. In a similar MC culture
model, TGF-β induced Col1a1, CTGF and PAI-1 was associated with increased levels of
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activation Kme marks (H3K4me1, H3K4me2 and H3K4me3) and reduced levels of
repressive marks (H3K9me2 and H3K9me3) at their promoters70. TGF-β also induced the
expression of SET7 HMT and enhanced its recruitment to ECM gene promoters. SET7 gene
silencing abolished TGF-β induced gene expression further confirming a key role of SET7
in fibrotic gene expression in MC. HG treatment of RMC also led to similar changes in
histone PTMs at fibrotic and cell cycle gene (p21) promoters69, 70. Interestingly, the
epigenetic effects of HG, including similar changes in promoter H3Kac and H3Kme as well
as SET7 recruitment, were significantly blocked by a TGF-β antibody, demonstrating a key
mediatory role of TGF-β in HG induced epigenetic histone modifications69, 70. Together
these results from in vitro studies support a critical role for epigenetic mechanisms in TGF-β
and HG induced pathological gene expression relevant to DN (Fig. 3).
Evidence for epigenetic changes in DN also comes from studies in animal models. One
report showed changes in global histone modifications are associated with the expression of
fibrotic and cell cycle genes involved in DN pathogenesis5. HDAC inhibitors showed
renoprotective effects, but it was not clear if these were due to inhibition of epigenetic or
non-epigenetic effects mediated by HDACs71. A recent study used ChIP assays for a more
focused assessment of genes associated with DN. Glomeruli from streptozotocin injected
type 1 diabetic (T1D) mice and T2D db/db mice exhibited increased expression of PAI-1
and p21 genes and this was associated with elevated levels of H3K9/14ac near Smad and
SP1 binding sites at their promoters compared to the respective non-diabetic controls. These
results demonstrate the in vivo relevance of HG and TGF-β induced H3K9/14ac in cultured
MC69. However, it clear that a single histone PTM does not fully represent the chromatin
status at these genes, but more likely a histone code of multiple PTMs. With this in mind,
another recent study profiled several histone PTMs in glomeruli from diabetic db/db mice
and control db/+ mice72. Results showed that relative to db/+ mice, glomeruli from db/db
mice exhibited increased RNA Polymerase II (Pol II) recruitment, enhanced levels of several
activation marks, and decreased levels of key repressive marks at the promoters of PAI-1
and RAGE (receptor for advanced glycation end products). These results suggest that
epigenetic mechanisms regulated by diabetes in vivo can co-operate to promote open
chromatin formation around the PAI-1 and RAGE promoters resulting in enhanced access to
transcription machinery and transcription of these genes in db/db mice. Furthermore, the
expression of several HATs, HDACs and HMTs were also increased, the most notable being
KAT5 (TIP60), HDAC7, HDAC9, SET2, SET4 and SET7. In this study, db/db mice were
also treated with or without Losartan, an Ang II type 1 receptor blocker (ARB) to test
whether the renoprotective effects of ARBs are associated with the inhibition of epigenetic
mechanisms. Losartan treatment for 10 weeks ameliorated key indices of DN, but did not
reverse all the epigenetic changes observed in the db/db mice72. Incomplete inhibition of
epigenetic changes associated with DN might be one explanation for the relative
inefficiency of ARBs to prevent progression to ESRD in many patients73. This study also
highlights the complexity of performing epigenome profiling with renal tissues from animal
models of a chronic progressive disease like DN and the need to evaluate various time
periods during disease progression. Similar studies with other treatment modalities, TGF-β
antibodies and RAGE inhibitors might provide novel information about the epigenetic
mechanisms in DN that may or may not be inhibited by these interventions.
Histone PTMs in vascular cells and monocytes under diabetic conditions.
Potential connections between epigenetics and metabolic memory
Chronic inflammation is a hallmark of diabetes complications, including DN where
macrophage infiltration and increased inflammatory gene expression have been observed in
the kidney. HG increased activation of NF-κB is a major mechanism of inflammatory gene
expression in vascular cells and monocytes relevant to diabetes complications and recently
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several studies have demonstrated the involvement of epigenetic modifications in these
events74, 75. HG induced NF-κB mediated inflammatory gene expression in THP-1
monocytes and promoted NF-κB binding in EC, key events in vascular diseases76, 77. In
monocytes, HG increased the recruitment of co-activator HATs CBP/p300, and augmented
the levels of active marks H3Kac and H4Kac to promote open chromatin formation at
inflammatory gene promoters78. HG actions on NF-κB activation were enhanced by HDAC
inhibitors and blocked by overexpression of HDACs, further supporting the role of histone
Kac78. Interestingly, profiling approaches with chromatin immunoprecipitation linked to
microarrays (ChIP-on-chip) revealed differential regulation of H3K4me2 and H3K9me2
marks at gene bodies of several genes in HG treated THP-1 monocytes79. Similar changes in
H3Kac, H3K4me2 and H3K9me2 at key genes were also found in blood monocytes
obtained from diabetic patients thereby demonstrating disease relevance78, 79. Furthermore,
ChIP-on-chip epigenome profiling of blood lymphocytes from T1D patients versus healthy
controls demonstrated significant variations in the repressive H3K9me2 mark at a subset of
genes associated with T1D, inflammation and autoimmunity 80. Recently, profiling of
several histone PTMs at chromosome 6 regions revealed key variations in H3K9ac at the
enhancer regions of two HLA genes whose single nucleotide polymorphisms are closely
linked to T1D81. These data support the involvement of epigenetic modifications in the
etiology of diabetes and potential cross talk between genetic and epigenetic variations that
however need further testing in bigger cohorts. In another in vitro study with monocytes, the
H3K4me transferase SET7, which regulates insulin gene expression in islets, was also
shown to be required for the maximal activation of a subset of NF-κB inducible
inflammatory genes in monocytes suggesting that SET7 may act as a co-activator of NF-
κB82. In vivo, enhanced inflammatory gene expression in macrophages from type 1 diabetic
mice was associated with increased SET7 recruitment and H3K4me2 at these gene
promoters82. Interestingly, HG induced expression of key inflammatory genes and increase
in histone Kac at their promoters in THP-1 monocytes were attenuated by the anti-
inflammatory agent Curcumin via inhibiting p300 and increasing HDAC2 levels83,
suggesting that certain natural products like curcumin can exert protective effects in diabetic
complications by attenuating epigenetic modifications. Further studies are needed to
determine how these data can be used for the development of epigenetic therapies for DN
and other diabetic complications.
HG also regulates epigenetic mechanisms in vascular cells including those related to DN
like ECs. Short term exposure of EC to HG increased the expression of p65, the active
subunit of NF-κB, and inflammatory genes via increased recruitment of SET7 and
H3K4me1 at these gene promoters 18. Notably, HG treatment triggered nuclear localization
and activity of SET7 in EC84, further demonstrating that HG can directly affect epigenetic
modulators. Diabetic retinopathy is associated with repression of the key anti oxidant gene
mitochondrial superoxide dismutase (SOD) in retinal EC. HG was shown to inhibit the SOD
gene by increasing promoter levels of the repressive mark H4K20me3 through upregulation
and increased recruitment of the corresponding methyl transferase SUV420H2 to the SOD
gene promoter19. Furthermore, HG also up-regulated inflammatory genes via inhibition of
the repressive mark H3K9me3 at their promoters in vascular smooth muscle cells, which can
play a key role in atherosclerosis and hypertension85. Overall, these studies clearly
demonstrate the epigenetic regulation of gene expression by HG in cells relevant to DN and
related vascular complications (Fig. 4).
As discussed earlier, prior exposure to hyperglycemia has been related to a metabolic
memory of long term sustained complications like despite subsequent glycemic control.
Since Histone Kme is a relatively stable epigenetic mark, a number of studies have
examined the hypothesis that persistently altered histone Kme at key pathological genes
might lead to their sustained up-regulation and metabolic memory. In support of this, it was
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demonstrated that enhanced inflammatory gene expression and migration in VSMC obtained
from T2D db/db mice relative to control db/+ mice even after being cultured for several
passages in vitro was associated with a persistent loss of the repressive mark H3K9me3 at
these gene promoters. Furthermore, in parallel there was a down-regulation of the
corresponding H3K9me3 methyl transferase SUV39H1 which was attributed at least in part
to increased levels of miR-125b in db/db mice, revealing a novel cross-talk between miRNA
actions and epigenetic components in diabetes85, 86. Similarly, sustained changes in
H3K4me1 and SET7 were implicated in the prolonged upregulation of p65 in EC that were
previously exposed to HG for short time periods, and these changes were mediated by
oxidant stress dependent mechanisms18. Furthermore, in a rat model of diabetic retinopathy
and metabolic memory, sustained downregulation of the SOD gene was attributed to
persistent increases in promoter levels of the repressive mark H4K20me3 and increased
expression of its methyl transferase SUV420H219. Together, these studies strongly suggest
that epigenetic mechanisms related to alterations in histone PTMs may be involved in
metabolic memory of DN and other complications (Fig 4). Further studies are needed to
understand how HG and diabetes drive these epigenetic events in vitro and in vivo, over
short and long time periods, and how they can be reversed to prevent the progression of
complications even after glycemic control. Importantly, additional studies with human
diabetic subjects experiencing metabolic memory are needed to extrapolate these
observations to clinical metabolic memory and glycemic variations.
High throughput Genomic and Epigenomic Approaches
Several techniques have been developed to analyze gene expression patterns and epigenetic
modifications in mammalian cells using microarrays and massively parallel next generation
DNA sequencing (NGS) platforms87–89. DNAme is analyzed using bisulfite conversion of
genomic DNA, digestion with methyl sensitive enzymes, immunoprecipitation of
methylated DNA, and affinity capture of methylated cytosines in DNA. DNA extracted from
these methods is hybridized to microarrays or sequenced using NGS platforms to obtain
genome-wide distribution of DNAme (methylome)89. Histone modifications are analyzed
using Chromatin immunoprecipitation (ChIP) assays in which DNA and proteins are cross
linked by fixing the tissue samples or treated cells with formaldehyde. DNA in the cross-
linked chromatin is sheared by sonication to smaller DNA fragments and
immunoprecipitated with antibodies against specific histone modifications.
Immunoprecipitated DNA is reverse cross-linked and then analyzed using PCR primers
specific to promoters or other genomic regions of interest to determine the genome locations
enriched with specific histone PTMs. ChIP can also be used to analyze enrichment of TFs,
histone modification enzymes and other epigenetic factors that interact with chromatin. This
has been extended to genomewide analysis by hybridization of ChIP-enriched DNA to
microarrays (ChIP-on-chip)90 or by NGS (sequencing) methods (ChIP-Seq)87. Advances in
NGS technologies have also led to the development of other novel techniques including
FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements)-Seq which allows
detection of accessible chromatin and regulatory elements based on differential cross-linking
efficiency of nucleosome enriched and depleted regions91. FAIRE-Seq and DNAse-Seq
have extended the capabilities of the widely used DNAse hypersensitivity assays to
determine regulatory or open chromatin regions genomewide92. Furthermore, RNA-Seq has
revolutionized transcriptome analysis in diverse cell types and disease conditions and led to
the detection of novel transcripts88. The major advantage of NGS is that, unlike microarrays,
no prior information about genomic DNA sequence is needed and the data obtained can be
used to quantitatively estimate the changes in gene expression and epigenetic modifications
genomewide. Integration of the transcriptome, DNA-methylome and ChIP-seq data can
yield extensive and comprehensive information about the epigenome state in diverse
pathophysiological conditions93, 94. Recently, the Encyclopedia of DNA Elements
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(ENCODE) project completed high-quality whole-genome functional annotations of the
human and mouse genomes and deposited the data in publicly available databases6, 95, 96.
This information along with resources from NIH Roadmap Epigenomics consortium (http://
www.roadmapepigenomics.org) are valuable reference tools to accelerate and catalyze new
research in epigenomics of human disease.
High through put approaches using microarray and NGS platforms have been successfully
used to profile epigenetic modifications or open chromatin (accessible) regions in
monocytes, lymphocytes79–81, pancreatic islets61, 62, 97, 98, or EC46 under diabetic
conditions. Similar studies in renal tissues from mouse models of DN and from diabetic
subjects are being performed in several laboratories and the results, when available, are
likely to yield novel insights into epigenome variations linked with DN pathogenesis.
Summary and Perspectives
The pathogenesis of DN involves complex interactions between metabolic and
hemodynamic factors with major roles being played by HG, TGF-β, AGEs and Ang II.
Signal transduction pathways and TFs regulated by these factors that lead to pathologic gene
expression have been extensively studied. Emerging evidence shows that epigenetic
mechanisms in chromatin including histone PTMs, DNAme and miRNAs might also play
key role in the etiology of diabetes and DN. Persistence of epigenetic modifications
triggered by diabetic stimuli could be one of the key mechanisms underlying metabolic
memory. A role for several HMTs and the corresponding histone PTMs has been
demonstrated in the expression of fibrotic and inflammatory genes associated with DN. But
the involvement of many others and mechanisms of their regulation by upstream signal
transduction pathways are still unknown. However, this is a rapidly expanding and dynamic
field and it is likely that, aided by the recent advances made by the Human Epigenome
project and ENCODE 6, 95, 96, other chromatin factors and epigenetic mechanisms related to
diabetes and DN will be revealed in the upcoming years. Epigenomics or EWAS may also
enable us to determine the functional significance of genetic variants in certain non-coding
and coding regions as well as cross talk between the genetic and epigenetic machinery.
Because epigenetic changes are potentially reversible in nature, there is an opportunity to
develop combination therapies with epigenetic drugs30 and antagomirs (miRNA
inhibitors)99 to complement the current treatments for DN. However, there are also
challenges to overcome. Since epigenetic patterns are cell specific, data from EWAS using
heterogeneous kidney tissues and biopsies could be difficult to interpret. Furthermore,
obtaining glomerular and tubular biopsies from affected individuals and matched controls
poses another major obstacle. Because inflammation is closely associated with most diabetic
complications including DN, another approach is to examine inflammatory cells like blood
monocytes that are obtained easily and non-invasively. Overall, it is anticipated that further
research in the field of epigenetics may lead to the identification of much needed new
biomarkers and drug targets for early detection and treatment of DN.
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Figure 1. Major pathways involved in the pathophysiology of diabetic nephropathy
Complex interactions between metabolic and hemodynamic factors regulate the
pathogenesis of diabetic nephropathy. Persistence of HG mediated damage including
epigenetic modifications even after return to normoglycemia can lead to metabolic memory
and increased risk for long term complications. TGF-β, transforming growth factor-β; AGEs,
advanced glycation end product; RAAS, rennin angiotensin aldosterone system; PKC,
protein kinase C; NF-κB, nuclear factor kappa-B; PTMs, posttranslational modifications;
ECM, extracellular matrix.
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Figure 2. Schematic diagram showing enrichment of histone modifications at various regulatory
elements in chromatin
Transcriptionally active chromatin is characterized by open chromatin states with
nucleosome depleted regions providing increased access to transcription factors (TF), RNA
polymerase II (Pol II) and other components of the transcription machinery (T). Whereas
repressed chromatin has a compact structure with higher density of nucleosomes and
restricted accessibility. In general, active gene promoters are enriched with H3K4me3,
H3K4me2 and H3/H4Kac, transcribed Exons (Ex) and Introns (Int) are enriched with
H3K36me3 and H3K79me3. Enhancers (Enh) are enriched with H3K4me1 and the histone
acetyl transferase p300 and active enhancers are marked by H3K4me2 and H3K27ac.
Repressed promoters are enriched with H3K9me2/3, H3K27me3, H4K20me3 and DNA
methylation (DNAme). Insulators (Ins) are enriched with the CCCTC-binding factor
(CTCF) and demarcate active and inactive chromatin regions. TB-TF binding sites; Kme-
lysine methylation; Kac-lysine acetylation.
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Figure 3. Epigenetic mechanisms involved in Diabetic Nephropathy
High glucose (HG), and TGF-β-transforming growth factor-beta1 (TGF-β) regulate
Extracellular matrix (ECM) genes and cell cycle genes by increasing active modifications
H3K9/14ac and H3K4me1/2/3, and inhibiting repressive marks H3K9me2/3 at these gene
promoters. TGF-β promotes the recruitment of CBP/p300 which increases H3K9/14ac and
chromatin access to Smads and SP1 transcription factors. CBP/p300 also regulates Smad
activity by direct acetylation. TGF-β mediated inhibition of HDAC1 and HDAC5 may also
play a role in increased H3K9/14ac. TGF-β induces SET7 expression and promotes its
recruitment to gene promoters, which increases H3K4me1/2. Similar epigenetic mechanisms
are induced by HG and they are blocked by TGF-β antibodies (TGF-β Ab) implicating TGF-
β as a major mediator of epigenetic events in Diabetic Nephropathy. R-Corepressors. HMT-
histone methyl transferases; HDAC-histone deacetylases; SP1B-SP1 binding sites; SBE-
Smad binding elements; Pr-promoter; Pol II-RNA Polymerase II; T- components of
transcription machinery.
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Figure 4. Histone Modifications and gene regulation in vascular complications
Diabetes enhances expression of NF-κB induced inflammatory genes (TNF-α, IL-6 and
MCP-1) and inhibits antioxidant stress genes superoxide dismutase (SOD) in monocytes and
vascular cells via multiple epigenetic mechanisms: A. in vascular smooth muscle cells,
diabetes increases miR-125b, which blocks SUV39H1 expression, leading to inhibition of
H3K9me3 (repressive mark) and recruitment of co-repressor HP1 at inflammatory gene
promoters resulting in increased inflammatory gene expression; B. In retinal endothelial
cells, expression of anti-oxidant genes such as SOD is repressed by HG induced
SUV420H2, which mediates a repressive modification H4K20me3. 3. In monocytes and
endothelial cells, diabetes conditions promote recruitment of co-activator Histone acetyl
transferase (p300) and H3K4methyl transferase SET7, which increase activation marks H3/
H4Kac and H3K4me respectively leading to enhanced NF-κB mediated inflammatory gene
expression. Persistence of these epigenetic modifications even after removal of the diabetic
stimuli might be an underlying mechanism involved in metabolic memory of diabetic
complications. Inf genes-inflammatory genes; SOD-Super oxide dismutase; Pr-promoter;
TSS-transcription start site; Pol II-RNA Polymerase II; T- components of transcription
machinery.
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